Announces Fourth Quarter and Full Year 2018 Financial Results and Update

Announces Fourth Quarter and Full Year 2018 Financial Results and Update

Israel - April 30, 2018 -

Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing and commercializing M-001, a universal

flu vaccine candidate currently undergoing a pivotal clinical efficacy Phase 3 trial, today announced its fourth quarter and full

year financial results for the year ended December 31, 2018 and provided a business update.

Quarter 2018 Financial Summary

are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.748(NIS/$US) as at

Year 2018 Financial Summary

of December 31, 2018, BiondVax had cash and cash equivalents and short-term investments of NIS 75.8 million ($20.24m) as compared

to NIS 71.38 million as of December 31, 2017.

Highlights and Recent Corporate Update

financial results are available in the Company's annual report on Form 20-F for the year ended December 31, 2018, which

was filed with the Securities and Exchange Commission on April 30, 2019.

(NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The proprietary technology

of the vaccine candidate, called M-001, utilizes a unique combination of conserved and common influenza virus peptides designed

to provide multi-season and multi-strain protection against current and future, seasonal and pandemic influenza. In a total of

6 completed Phase 1/2 and Phase 2 clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated,

and immunogenic. An additional Phase 2 trial is being conducted by the NIH/NIAID is the US. As well, BiondVax is currently conducting

a large pivotal clinical efficacy Phase 3 trial in Europe. Please visit www.biondvax.com.

E. Phillipson | +972 8 930 2529 | j.phillipson@biondvax.com

press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such

as "expect," "believe," "intend," "plan," "continue," "may,"

"will," "anticipate," and similar expressions are intended to identify forward-looking statements. These

forward-looking statements reflect the management's current views with respect to certain current and future events and

are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected

by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution

and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval

of the new manufacturing facility; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials

and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability

of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our vaccine candidate

will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United

States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and

the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company

is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2018

filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov,

and in the Company's periodic filings with the SEC. We undertake no obligation to revise or update any forward-looking statement

thousands, except share and per share data

OF COMPREHENSIVE INCOME

thousands, except per share data